Association between tumour necrosis factor-α inhibitors and risk of serious infections in people with inflammatory bowel disease:nationwide Danish cohort study by Nyboe Andersen, Nynne et al.
Syddansk Universitet
Association between tumour necrosis factor- inhibitors and risk of serious infections
in people with inflammatory bowel disease
nationwide Danish cohort study
Nyboe Andersen, Nynne; Pasternak, Björn; Friis-Møller, Nina; Andersson, Mikael; Jess, Tine
Published in:
BMJ (Clinical research ed.)
DOI:
10.1136/bmj.h2809
Publication date:
2015
Document version
Publisher's PDF, also known as Version of record
Document license
CC BY-NC
Citation for pulished version (APA):
Nyboe Andersen, N., Pasternak, B., Friis-Møller, N., Andersson, M., & Jess, T. (2015). Association between
tumour necrosis factor- inhibitors and risk of serious infections in people with inflammatory bowel disease:
nationwide Danish cohort study. BMJ (Clinical research ed.), 350, [h2809]. DOI: 10.1136/bmj.h2809
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 09. Sep. 2018
RESEARCH
1
 open access
the bmj | BMJ 2015;350:h2809 | doi: 10.1136/bmj.h2809
1Department of Epidemiology 
Research, Statens Serum 
Institute, Artillerivej 5, 2300 
Copenhagen, Denmark
2Department of Infectious 
Disease, Odense University 
Hospital, Odense, Denmark
Correspondence to: N Nyboe 
Andersen nyna@ssi.dk
Additional material is published 
online only. To view please visit 
the journal online (http://dx.doi.
org/10.1136/bmj.h2809)
Cite this as: BMJ 2015;350:h2809
doi: 10.1136/bmj.h2809
Accepted: 19 May 2015
Association between tumour necrosis factor-α inhibitors and risk 
of serious infections in people with inflammatory bowel disease: 
nationwide Danish cohort study
Nynne Nyboe Andersen,1 Björn Pasternak,1 Nina Friis-Møller,2 Mikael Andersson,1 Tine Jess1 
ABSTRACT
ObjeCtive
To investigate whether people with inflammatory 
bowel disease treated with tumour necrosis factor-α 
(TNF-α) inhibitors are at increased risk of serious 
infections.
Design
Nationwide register based propensity score matched 
cohort study.
setting
Denmark, 2002-12.
PartiCiPants
The background cohort eligible for matching 
comprised 52 392 people with inflammatory bowel 
disease, aged 15 to 75 years, of whom 4300 were 
treated with TNF-α inhibitors. To limit confounding, 
a two stage matching method was applied; firstly 
matching on age, sex, disease duration, and 
inflammatory bowel disease subtype, and secondly 
matching on propensity scores (1:1 ratio); this yielded 
1543 people treated with TNF-α inhibitors and 1543 
untreated to be included in the analyses.
Main OutCOMe Measures
The main outcome was any serious infection, defined 
as a diagnosis of infection associated with hospital 
admission. Cox regression was used to estimate 
hazard ratios for two risk periods (90 and 365 days 
after the start of TNF-α inhibitor treatment). Hazard 
ratios of site specific serious infections were obtained 
solely for the 365 days risk period.
results
Within the 90 days risk period, 51 cases of infection 
were observed in users of TNF-α inhibitors (incidence 
rate 14/100 person years), compared with 33 cases in 
non-users (9/100 person years), yielding a hazard ratio 
of 1.63 (95% confidence interval 1.01 to 2.63). Within 
the risk period of 365 days, the hazard ratio was 1.27 
(0.92 to 1.75). In analyses of site specific infections, 
the hazard ratio was above 2 for several of the 
subgroups but only reached statistical significance for 
skin and soft tissue infections (2.51, 1.23 to 5.12).
COnClusiOns
This nationwide propensity score matched cohort 
study suggests an increased risk of serious infections 
associated with use of TNF-α inhibitors within the first 
90 days of starting treatment and a subsequent 
decline in risk. This calls for increased clinical 
awareness of potential infectious complications 
among people with inflammatory bowel disease using 
these drugs, especially early in the course of 
treatment.
Introduction
Tumour necrosis factor-α (TNF-α) inhibitors are highly 
effective in the treatment of several immune mediated 
diseases, including inflammatory bowel diseases. The 
most commonly used TNF-α inhibitors in people with 
inflammatory bowel disease are infliximab, adalim-
umab, and certolizumab pegol. All three drugs are 
approved for the treatment of Crohn’s disease, whereas 
only infliximab and adalimumab are approved for the 
treatment of ulcerative colitis.1-6
Since the pro-inflammatory cytokine TNF-α plays an 
important role in host defence, treatment with TNF-α 
inhibitors has been subject to extensive post-marketing 
safety assessment, including the risk of infections. 
Studies assessing the risk of serious infections in peo-
ple treated with TNF-α inhibitors for rheumatoid arthri-
tis have gradually revealed a largely coherent pattern of 
a moderately increased risk of serious infections in the 
initial phase of treatment and a subsequent decline in 
risk.7-10 Data are, however, less clear when it comes to 
the risk of serious infections in people treated with 
TNF-α inhibitors for inflammatory bowel diseases. A 
meta-analysis based on 22 randomised controlled tri-
als11 and a pooled analysis of 10 randomised controlled 
trials12 did not suggest an increased risk of serious infec-
tions in people with inflammatory bowel disease treated 
with TNF-α inhibitors compared with placebo. However, 
randomised controlled trials often represent selected 
patient populations, which is why post-marketing 
observational studies are essential to evaluate safety in 
a real world setting. A register based cohort study of 
people with inflammatory bowel disease did not find an 
increased risk of serious infections associated with 
TNF-α inhibitor treatment compared with propensity 
score matched patients treated with thiopurines.13 
WhAT IS AlReAdy knoWn on ThIS TopIC
Tumour necrosis factor-α (TNF-α) inhibitors are highly effective in the treatment of 
several immune mediated diseases, including inflammatory bowel disease
However, the risk of potential adverse events, including serious infections, remains 
a concern
Meta-analyses and population based studies investigating the association 
between TNF-α inhibitors and serious infections in people with inflammatory bowel 
disease are few and have yielded ambiguous results
WhAT ThIS STudy AddS
This nationwide cohort study suggests that treatment of inflammatory bowel 
disease with TNF-α inhibitors is associated with an increased risk of serious 
infections within the first three months of the start of treatment and a subsequent 
decline in risk
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 However, another register based study reported an 
increased risk of serious infections associated with 
infliximab use in people with inflammatory bowel 
 disease,14  as did a study based on data from the Food 
and Drug Administration Adverse Event Reporting 
 System.15 Thus the risk of infections associated with 
use of TNF-α inhibitors in people with inflammatory 
bowel disease is unclear. We conducted a nationwide 
population based cohort study using linked registry 
data to investigate the risk of serious infections in 
 Danish people with inflammatory bowel disease 
treated with TNF-α inhibitors.
Methods
Using the Danish civil registration system,16  which con-
tains information on the sex, date of birth, and vital 
status of all Danish citizens, we identified a source pop-
ulation, including all individuals aged 15-75 years living 
in Denmark between 2002 and 2012. By use of the 
unique personal identification number assigned to all 
Danish citizens at birth, we could link the source popu-
lation to other national registries. From the national 
patient registry,17 a registry containing information on 
all hospital admissions in Denmark since 1977, and 
since 1995 extended to include all outpatient visits and 
emergency room contacts, we identified people with 
inflammatory bowel disease from ICD-8 and ICD-10 
codes (international classification of diseases, eighth 
and 10th revisions, respectively): ICD-8 codes 56300-02 
and 56308-09 and ICD-10 code K50 for Crohn’s disease; 
ICD-8 codes 56319 and 56309 and ICD-10 code K51 for 
ulcerative colitis. Furthermore, we used the national 
patient registry to ascertain history of comorbidities 
and study outcomes based on ICD-10 codes.
From the Danish drug prescription registry,18  estab-
lished in 1995 and containing individual level informa-
tion on all prescriptions redeemed at Danish 
pharmacies, we obtained data on drugs. Although the 
treatment with TNF-α inhibitors for inflammatory 
bowel disease were introduced in Denmark in 1999, we 
started the study in 2002 and excluded people who used 
TNF-α inhibitors before the start of the study; in this 
way, early drug users who were treated in the first years 
after the introduction of TNF-α inhibitors (who are 
likely to be different from the drugs’ eventual stable 
user population, in terms of factors such as disease 
severity and therefore may introduce bias19) were not 
eligible for inclusion. We also excluded people with a 
diagnosis of HIV infection (ICD-10 code B20; ICD-8 
codes 07983 and Y4149) and those with a history of 
organ or tissue transplantation (ICD-10 code Z94; ICD-8 
not available).
Drug use
To assure completeness of data we obtained informa-
tion on use of TNF-α inhibitors (including infliximab, 
adalimumab, and certolizumab pegol) from four 
sources: manually collected data on a nationwide 
cohort of all Danish people with inflammatory bowel 
disease treated with infliximab between its introduction 
in 1999 and 2005; data from the Danish Ministry of 
Health, which after 2003 has kept track of TNF-α inhib-
itor treatment in all Danish hospital settings through 
procedure codes registered in the national patient reg-
istry; information on TNF-α inhibitor treatment 
reported to the Danish Crohn Colitis Database (a data-
base designed to prospectively register Danish resi-
dents with inflammatory bowel disease20) during 
2002-10; and information from the Danish drug pre-
scription registry on prescriptions for adalimumab and 
certolizumab pegol during the study period (there are 
no data on infliximab use from this data source as intra-
venous infusion of the drug is confined to the hospital 
setting). Some patients were registered in more than 
one of the four sources; however, we considered one 
registration as sufficient to be defined as having used 
drugs. We defined patients as TNF-α inhibitor users 
from the date of first dose and onwards; thus we catego-
rised patients as ever users once they had been 
“exposed” to the drug.
study outcomes
The main outcome was any serious infections, defined 
as a diagnosis of infection associated with hospital 
admission (including primary and secondary dis-
charge diagnoses) after cohort entry (outpatient diag-
noses of infections were not included). Supplementary 
etable 1 shows the infection diagnoses included in the 
main outcome (any serious infection) and subdivided 
into six groups of site specific infections. These 
included respiratory tract infections, gastrointestinal 
infections, urological or gynaecological infections, 
skin and subcutaneous tissue infections, sepsis, and 
other infections (including opportunistic infections 
and tuberculosis).
Propensity score model approach
To take into account potential confounders we used 
propensity score methods. We calculated the propen-
sity scores as the predicted probability of starting treat-
ment with TNF-α inhibitors conditional on variables 
thought to be either confounders or predictors for the 
outcome. These variables included, among others, 
socioeconomic status; degree of urbanisation; comor-
bidities; concurrent drug use; history of gastrointesti-
nal or anal fistula, abscess, or fissure; and 
gastrointestinal surgery (supplementary etable 2 pres-
ents a list of all variables included in the propensity 
score). In preliminary analyses we attempted propen-
sity score adjustment on the full background cohort. 
However, because of substantial heterogeneity of risk 
estimates across propensity score strata (likely because 
the propensity score was highly discriminative (that is, 
a high C statistic) given substantial differences in char-
acteristics between TNF-α inhibitor users and non-us-
ers), which violates the basic assumptions of this 
approach, it was abandoned. In the interest of mini-
mising bias and obtaining reliable estimates from a 
valid model, we subsequently opted for a propensity 
score matching strategy. A well balanced match was 
considered as a standardised difference between users 
and non-users of TNF-α inhibitors below 10% for any 
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given variable. Firstly, we attempted matching in a 
ratio of 1:4 for users and non-users, respectively, but we 
found matches for less than half of the users and 
matching yielded only approximately two matches for 
each user and use groups that were poorly matched; 
we therefore abandoned this approach. Secondly, we 
attempted matching in a ratio of 1:1 for users and 
non-users, respectively, with all baseline characteris-
tics included in the propensity score. This left a well 
balanced cohort; however, a substantial number of 
users could not be included owing to no appropriate 
matches. Therefore we removed the two variables—
azathioprine use and oral corticosteroid use—that had 
the most discriminatory influence (large differences in 
prevalence between users and non-users and high 
standardised differences before matching) from the 
propensity score. Matching on this modified propen-
sity score in a 1:1 ratio allowed a larger number of 
TNF-α inhibitors users (and corresponding non-user 
matches) to be included while maintaining a cohort 
well balanced on all matching characteristics; we 
therefore selected this as the final model (supplemen-
tary efigure illustrates the standardised differences 
before and after matching on propensity scores). The 
strategy for incorporation of propensity scores is 
described below and the two variables that were 
removed from the propensity score were instead 
adjusted for in a multivariable Cox regression model.
statistical analyses
The matching process was done in two consecutive 
stages. Firstly, to remove users of TNF-α inhibitors with 
no potential matches, we matched on the following 
fixed factors representing key characteristics; sex, age 
(in five year intervals), inflammatory bowel disease type 
(Crohn’s disease or ulcerative colitis), and time since 
diagnosis (<1, 1-4, 5-9, 10-19, and ≥20 years) in a 1:n vari-
able ratio. Next, by use of logistic regression, we esti-
mated the individual propensities for initiating TNF-α 
inhibitor treatment. We chose the nearest neighbor cal-
iper matching method, as this method seems to gener-
ate the most precise matching with lowest potential for 
bias and is appropriate in relatively small cohorts.21 
Pairs of TNF-α inhibitor users and non-users with near-
est propensity scores were matched (ratio 1:1) based on 
the logit of the propensity score with a caliper width of 
0.222 of the standard deviation of the propensity score. 
In addition we assigned non-users the date of the first 
day of TNF-α inhibitor use of their user matches as their 
first day of follow-up.
Using Cox proportional hazards models, we esti-
mated hazard ratios with 95% confidence intervals for 
serious infections in propensity score matched users 
versus non-users of TNF-α inhibitors, with days since 
the start of treatment as the underlying timescale. We 
assessed the risk of any serious infection in two risk 
periods, of 90 days and 365 days, and additionally in 
subgroups according to sex and inflammatory bowel 
disease subtype. Risk estimates of site specific infec-
tions were assessed in the 365 days risk period alone 
(owing to limited power for the 90 day risk period). 
 Furthermore, we performed a subanalysis estimating 
hazard ratios according to accumulated number of 
TNF-α inhibitor doses compared with non-users. 
Patients were followed from cohort entry until the date 
of first diagnosis of infection, loss to follow-up (emigra-
tion or disappearance), death, end of study (31 Decem-
ber 2012), or end of follow-up, whichever event occurred 
first. Risk estimates were adjusted for oral corticoste-
roid use and azathioprine use at baseline, as these vari-
ables were not included in the propensity score.
We did some supplementary analyses. To test for con-
founding by indication, we included an analysis with 
an active comparator drug. We compared the risk of 
infections in patients who started TNF-α inhibitors with 
those who started azathioprine. Although these two 
drugs are often used in combination in practice, in the 
interest of isolating associations attributable to one 
specific drug, in this analysis we only included patients 
who started monotherapy with the respective drug and 
had no history of use of the other drug—that is, patients 
starting TNF-α inhibitors had no history of azathioprine 
use and vice versa. Furthermore, we estimated the 
effects of a potential unmeasured or incompletely mea-
sured confounder on the main outcome, by using the 
array approach described by Schneeweiss.23
Because risk estimates might be more precise when 
assessing the risk of an adverse event while receiving 
treatment, we conducted an analysis with a time vary-
ing drug use definition (divided into current and past 
use and compared with non-users). Reliable data on 
specific TNF-α inhibitors were available only from one 
of the drug sources (the national patient registry) and 
only for 2005 and onwards; hence the analysis was 
based on a subcohort with data on TNF-α inhibitor use 
from the national patient registry during this period. 
Patients contributed follow-up as current users in a 
period set from the date of each administered dose and 
as long as a newly administered TNF-α inhibitor was 
registered in a TNF-α inhibitor drug specific interval 
(eight weeks for infliximab, two weeks for adalimumab, 
and four weeks for certolizumab pegol, in accordance 
with current treatment guidelines). We allowed for a 
gap of up to four weeks between the end of the interval 
of the latest dose and the date of the subsequent dose 
being administered to account for irregularities in the 
dosage interval. Lastly, because matching on the pro-
pensity score had led to the exclusion of a large number 
of patients who used TNF-α inhibitors, we did an analy-
sis estimating hazard ratios of the main outcome based 
on the entire cohort matched on fixed factors, but not 
on propensity scores.
To confirm the proportional hazards model assump-
tions, we tested for martingale residuals for study expo-
sure and the two baseline adjusted variables 
(azathioprine use and corticosteroid use). Based on 
visual inspection, no violation of the assumptions was 
detected. We imputed data for the one variable that had 
missing values (0.8% missing for socioeconomic status; 
see supplementary etable 2) using the mode value. Loss 
to follow-up was negligible (1.1%) and therefore not 
 further assessed.
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Analyses were carried out using SAS version 9.4 
(Cary, NC). We considered differences to be statistically 
significant when the 95% confidence intervals did not 
overlap 1.0 or when the P value was <0.05 (all tests were 
two sided).
Patient involvement
There was no patient involvement in this study.
Results
From the source population of 4 160 526 people, we iden-
tified 53 252 people with inflammatory bowel disease (fig 
1). A total of 860 (2%) patients were excluded owing to a 
diagnosis of HIV/AIDS, history of organ or tissue trans-
plantation, or use of tumour necrosis factor-α (TNF-α) 
inhibitors before entry to the cohort. This left a back-
ground cohort of 52 392 people with inflammatory bowel 
disease, among whom 4300 received TNF-α inhibitors. In 
the background cohort the patients who used TNF-α 
inhibitors were characterised by having a younger median 
age, higher proportion with Crohn’s disease, and a higher 
prevalence of intestinal surgery and inflammatory bowel 
disease related drug use compared with cohort members 
who were non-users (see supplementary etable 3).
Matching on fixed factors (84 TNF-α inhibitor users 
were excluded because of no potential match) and pro-
pensity scores (2673 TNF-α inhibitor users were 
excluded because of no potential match) yielded 1543 
patients who used TNF-α inhibitors (infliximab, 
n=1243; adalimumab, n=201; certolizumab pegol, n=3, 
unspecified, n=96) and 1543 non-users who were 
included in the study cohort. Users of TNF-α inhibitors 
in the matched cohort had a mean age of 44.6 (SD 14.5) 
years, 57% were women, and 57% had ulcerative colitis 
(table 1). The study groups were well balanced on all 
baseline characteristics included in the propensity 
score and as fixed matching variables; oral corticoste-
roid use and azathioprine use were more common 
among patients treated with TNF-α inhibitors (table 1 
and supplementary efigure 1).
risk of any serious infection
Table 2 shows hazard ratios of any serious infections, 
comparing users of TNF-α inhibitors with matched 
non-users. Within 90 days after the start of treatment 51 
cases of serious infections were observed in TNF-α 
inhibitor users (incidence 14/100 person years, 95% 
confidence interval 11 to 18) compared with 33 (inci-
dence 9/100 person years, 6 to 13) in non-users, yielding 
a hazard ratio of 1.63 (95% confidence interval 1.01 to 
2.63). Subgroup analyses revealed a significantly 
increased hazard ratio for women (2.08, 95% confi-
dence interval 1.09 to 3.96) but not for men (1.20, 0.57 to 
2.50). Point estimates were nominally increased for 
both ulcerative colitis and Crohn’s disease (1.83, 0.96 to 
3.47 and 1.39, 0.67 to 2.88, respectively).
Within the 365 days risk period, 107 cases of serious 
infections (incidence 8/100 person years, 95% confi-
dence interval 7 to 10) were observed in users of TNF-α 
inhibitors compared with 78 (incidence 6/100 per-
son-years, 5 to 7) in non-users. The hazard ratio was 1.27 
(95% confidence interval 0.92 to 1.75). For men the haz-
ard ratio was 1.18 (0.73 to 1.91) and for women it was 1.34 
(0.87 to 2.08). The hazard ratio was nominally increased 
for ulcerative colitis (1.45, 0.92 to 2.27) but not for 
Crohn’s disease (1.05, 0.65 to 1.69). 
In the subanalysis of accumulated number of TNF-α 
inhibitor doses, the risk of serious infections was sig-
nificantly increased in patients receiving a single dose 
(hazard ratio 1.64, 95% confidence interval 1.06 to 2.53) 
and decreased thereafter in those receiving two or three 
doses (1.18, 0.79 to 1.78) and four doses or more (1.06, 
0.66 to 1.69, fig 2).
risk of site specific serious infections
Among the six site specific infection groups, the hazard 
ratio was above 2 for several of the subgroups, includ-
ing sepsis (2.45, 95% confidence interval 0.65 to 9.19), 
urological or gynaecological infections (2.31, 0.64 to 
8.29), and skin and soft tissue infections (2.51, 1.23 to 
5.12), but only reached statistical significance for the 
last category (table 3). Among the 107 cases of serious 
infections detected in users of TNF-α inhibitors, the 
most common infections were pneumonia (24%) and 
gastroenteritis (17%). For skin and soft tissue infec-
tions, the diagnoses were dominated by abscesses, car-
buncles, and furuncles (35%), erysipelas (19%), and 
herpes infections (12%) (see supplementary etable 4). 
No cases of tuberculosis were detected among patients 
who used TNF-α inhibitors.
supplementary analyses
Several supplementary analyses were performed to 
check the robustness of results. In the head to head 
analysis comparing patients who used TNF-α inhibitor 
Source population living in Denmark and
aged 15-75 years in 2002-12 (n=4 160 526)
People with diagnosis of inflammatory
bowel disease (n=53 252)
HIV infection-free people with inflammatory
bowel disease with no previous use of TNF-α inhibitors
and no history of organ or tissue transplantation,
among whom 4300 used TNF-α inhibitors (n=52 392)
Excluded (multiple causes possible) (n=860):
  HIV infection (n=137)
  History of tissue or organ transplantation (n=317)
  Receipt of TNF-α inhibitor before cohort entry (n=409)
Total cohort with potential match aer matching on xed
  factors (n=50 307):
    TNF-α inhibitor users (n=4216)
    TNF-α inhibitor non-users (n=46 091)
Final cohort matched on xed factors and propensity scores
  (n=3086):
    TNF-α inhibitor users (n=1543)
    TNF-α inhibitor non-users (n=1543)
Fig 1 | Formation of study cohort. Fixed factors included 
age, sex, duration of disease, and inflammatory bowel 
disease subtype. tnF-α inhibitors=tumour necrosis factor 
inhibitors
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monotherapy with those using azathioprine monotherapy 
(see patient characteristics in supplementary etable 5), 
the hazard ratios for serious infections associated with 
use of TNF-α inhibitors were 2.17 (0.85 to 5.52) for the 90 
day risk period and 2.05 (0.97 to 4.36) for the 365 day 
risk period (table 4). The effect of a potential unmea-
sured confounder was tested on the main outcome 
within the 90 day risk period, by assuming a wide 
range of combinations of confounder prevalence in the 
user group and strengths of the association between 
the confounder and infections (see supplementary 
etable 6). For example, assuming a confounder, such 
as smoking, was present in 30% of the TNF-α inhibitors 
user group and 20% of the non-user group, and if the 
confounder increased the risk of infections twofold, 
the observed point estimate of 1.63 would have been 
biased by 8% and the confounder adjusted estimate 
would be 1.50. The analyses using an alternative time 
varying definition for drug use were based on a 
matched subcohort of 1472 people who used TNF-α 
inhibitors and 1472 non-user controls. Within 90 days 
of follow-up, the hazard ratio for current use was 1.70 
(1.03 to 2.81) and was not estimable for past use 
because of no outcome events in this group. For the 365 
day risk period, the hazard ratios were 1.29 (0.90 to 
1.85) for current use and 1.20 (0.74 to 1.95) for past use 
(see supplementary etable 7). The analyses based on 
the cohort matched on fixed factors but not on propen-
sity scores, including 4216 users of TNF-α inhibitors 
and 46 091 non-users, yielded higher risk estimates but 
a similar risk pattern as the main analysis, with hazard 
ratios of 1.81 (1.45 to 2.24) for the 90 days risk period 
and 1.52 (1.33 to 1.74) for the 365 days risk period (see 
supplementary etable 8). Supplementary etable 9 
shows the characteristics of users of TNF-α inhibitors 
excluded from the propensity score matched cohort. 
Excluded patients were characterised by having more 
severe inflammatory bowel disease, as witnessed by a 
higher prevalence of inflammatory bowel disease 
related drug use and surgery, but had a lower preva-
lence of general comorbidities and use of other drugs 
and were mostly patients with Crohn’s disease.
discussion
In this nationwide propensity score matched cohort 
study we found a statistically significant 63% increased 
risk of serious infections associated with TNF-α inhibi-
tor treatment in people with inflammatory bowel dis-
ease within 90 days of the start of treatment. Assessing 
the risk of serious infection during a longer follow-up 
period of 365 days, the association was attenuated and 
was no longer significant. For site specific serious infec-
tions, we found increased point estimates for sepsis, 
urological or gynaecological infections, and skin and 
soft tissue infections; these analyses should, however, 
be interpreted cautiously because of limited power.
strengths and limitations of this study
The primary strength of this study is the nationwide 
register based design, providing a cohort covering the 
entire Danish population with inflammatory bowel 
table 1 | Characteristics of matched study cohort of tumour necrosis factor-α (tnF-α) 
inhibitor users and non-users with inflammatory bowel disease. values are numbers 
(percentages) of patients unless stated otherwise
Characteristics
users of tnF-α 
inhibitors (n=1543)
non-users of tnF-α 
inhibitors (n=1543)
Mean (SD) age (years) 44.6 (14.5) 44.6 (14.6)
Male sex 656 (43) 656 (43)
Inflammatory bowel disease subtype:
 Crohn’s disease 667 (43) 667 (43)
 Ulcerative colitis 876 (57) 876 (57)
Disease duration (years):
 <1 392 (25) 392 (23)
 1-4 530 (34) 530 (34)
 5-9 360 (23) 360 (23)
 10-19 238 (15) 238 (15)
 ≥20 23 (2) 23 (2)
Place of birth:
 Denmark 1473 (96) 1477 (96)
 Europe 32 (2) 25 (2)
 Other countries 38 (3) 41 (3)
socioeconomic status
Employment:
 Unknown, basic, or no qualifications 560 (36) 618 (40)
 Medium level qualifications 212 (14) 200 (13)
 High level qualifications 146 (10) 151 (10)
 Self employed or coworking spouse 68 (4) 54 (4)
 Outside labour market 424 (28) 384 (25)
 Pensioned 133 (9) 136 (9)
Degree of urbanisation
Population density (inhabitants per km2):
 ≤49 106 (7) 116 (8)
 50-99 465 (30) 446 (29)
 100-199 341 (22) 343 (22)
 ≥200 160 (10) 180 (12)
Copenhagen suburbs 306 (20) 313 (20)
Copenhagen 165 (11) 145 (9)
Comorbidities
Gastrointestinal:
 Surgery 115 (8) 104 (7)
 Intestinal, anal, rectal fissure, fistula, abscess 34 (2) 25 (2)
Cardiovascular disease 135 (9) 140 (9)
Chronic pulmonary disease 86 (6) 77 (5)
Diabetes 104 (7) 108 (7)
Liver disease 23 (2) 18 (1)
Renal disease 16 (1) 14 (1)
Rheumatic disease 101 (7) 68 (4)
Cancer 50 (3) 36 (2)
Previous infections* 117 (8) 105 (7)
Non-inflammatory bowel disease drugs†:
 Cardiovascular 347 (23) 385 (25)
 Antianemic 231 (15) 221 (14)
 Pulmonary antiobstructive 173 (11) 172 (11)
 Antimicrobials 722 (47) 703 (46)
No of prescription drugs used in past 6 months:
 0 110 (7) 86 (6)
 1 or 2 257 (17) 256 (17)
 3 or 4 244 (16) 278 (18)
 ≥5 932 (60) 923 (60)
Inflammatory bowel disease drugs†
 5-aminosalicylic acid/sulfasalazine 670 (43) 686 (45)
 Intestinal corticosteroids 283 (18) 300 (19)
 Methotrexate, cyclosporine, cyclophosphamide 42 (3) 20 (1)
 Azathioprine‡ 690 (45) 217 (14)
 Oral corticosteroids‡ 861 (56) 303 (20)
Continued
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 disease with minimal loss to follow-up and indepen-
dent ascertainment of exposure and outcomes. A vali-
dation study with assessment of nearly 800 patients 
estimated the completeness of registration of inflamma-
tory bowel disease in the national patient registry to be 
94%, whereas the estimated validity, expressed as the 
proportion of confirmed diagnoses in the registry, was 
97% for Crohn’s disease and 90% for ulcerative colitis.24 
A complete treatment history could be obtained for all 
patients treated with TNF-α inhibitors, which allowed 
follow-up from the start of treatment hence avoiding 
prevalent user bias.25 Furthermore, we believe that our 
outcome definition (infections associated with hospital 
admission) is properly suited to identify serious infec-
tions that are potentially life threatening (as opposed to 
an outcome definition that also includes outpatient 
diagnoses).
The study also has limitations. In the interest of inter-
nal validity of the analyses, that is to minimise bias, we 
applied matching on fixed variables and propensity 
scores. Use of TNF-α inhibitors was relatively uncom-
mon in Denmark during the study period (9% of the 
background cohort were treated with the drugs); this 
implies that patients with the most severe disease were 
those who received this treatment. Finding adequate 
non-user matches for these patients was difficult, as 
ideal controls should have the same distribution of 
characteristics to enable the estimation of unbiased 
risk. This phenomenon was mirrored by the fact that a 
relatively low number of patients who were treated with 
TNF-α inhibitors in the background cohort could be 
included in the final matched cohort. Thus, while our 
matching method maximised internal validity, it may 
potentially have influenced the generalisability of the 
results. Therefore we performed a supplementary anal-
ysis including the majority of users and non-users of 
TNF-α inhibitors (only a few patients were excluded as 
patients were only matched on fixed factors, such as 
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35
No of patients
No of events
Each dose category is compared to TNF-α inhibitor non-users
1326
43
913
29
Fig 2 | risk of any serious infection according to 
accumulated number of tumour necrosis factor-α (tnF-α) 
inhibitor doses in users compared with non-users. error 
bars indicate 95% confidence intervals
table 1 | Characteristics of matched study cohort of tumour necrosis factor-α (tnF-α) 
inhibitor users and non-users with inflammatory bowel disease. values are numbers 
(percentages) of patients unless stated otherwise
Characteristics
users of tnF-α 
inhibitors (n=1543)
non-users of tnF-α 
inhibitors (n=1543)
Healthcare use in past year
No of hospital admissions:
 0 872 (57) 915 (60)
 1 or 2 539 (35) 502 (33)
 ≥3 132 (9) 126 (8)
No of outpatient contacts:
 0 371 (24) 352 (23)
 1 or 2 944 (61) 1007 (65)
 ≥3 228 (15) 184 (12)
The cohort was matched on fixed factors (sex, age, disease duration, and inflammatory bowel disease subtype) 
and propensity scores. All characteristics are as current at cohort entry unless stated otherwise.
*Defined as previous infections associated with hospital admission within one year before cohort entry.
†As registered within one year before cohort entry.
‡Not included in propensity score.
table 2 | Hazard ratios for any serious infection in users of tumour necrosis factor-α (tnF-α) inhibitors compared with matched non-users within 90 days 
and 365 days risk periods and according to sex and inflammatory bowel disease subtype
variables
users of tnF-α inhibitors non-users of tnF-α inhibitors Hazard ratio 
(95% Ci)no of patients no of events no of patients no of events
90 days risk period
Main analysis 1543 51 1543 33 1.63 (1.01 to 2.63)
Sex:
 Men 656 17 656 17 1.20 (0.57 to 2.50)
 Women 887 34 887 16 2.08 (1.09 to 3.96)
Inflammatory bowel disease subtype:
 Ulcerative colitis 876 32 876 18 1.83 (0.96 to 3.47)
 Crohn’s disease 667 19 667 15 1.39 (0.67 to 2.88)
365 days risk period
Main analysis 1543 107 1543 78 1.27 (0.92 to 1.75)
Sex:
 Men 656 48 656 36 1.18 (0.73 to 1.91)
 Women 887 59 887 42 1.34 (0.87 to 2.08)
Inflammatory bowel disease subtype:
 Ulcerative colitis 876 67 876 38 1.45 (0.92 to 2.27)
 Crohn’s disease 667 40 667 40 1.05 (0.65 to 1.69)
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age and sex, and not on propensity scores) and found 
estimates to reveal a similar pattern as in our main anal-
ysis, although the magnitude of association was stron-
ger in the supplementary analysis. This would be 
consistent with the notions that the population 
included in the main analysis is representative of the 
overall background population and that propensity 
score matching offered substantial control for 
 confounders.
To further assess the impact of disease severity as a 
confounder, we compared the risk of infection 
between patients who used TNF-α inhibitors and 
those who used azathioprine; although this analysis 
was based on a low number of patients, results did 
not indicate confounding by indication. We used the 
array approach to test for residual confounding due to 
unmeasured or incompletely measured confounders, 
which showed that such a confounder would have to 
be strongly associated with the study outcome and 
that the difference in prevalence of such a confounder 
between users and non-users would have to be rather 
large to explain the observed point estimate. For 
instance, adjustment for a confounder that increases 
the risk of serious infections twofold and with an 
absolute prevalence difference of 10% between users 
and non-users of TNF-α inhibitors would only margin-
ally attenuate the observed point estimate. However, 
the observed lower bound of the 95% confidence limit 
was close to 1.0; thus, adjustment for the confounder 
in the hypothetical scenario would likely render 
results non-significant.
Although we defined drug use according to the inten-
tion to treat principle (ever or never users) in our main 
analysis, assessment of the risk of serious infections 
while receiving treatment might give more precise risk 
estimates. We therefore did a robustness analysis using 
a time varying definition for drug exposure. Overall, 
the risk estimates for current use in this analysis were 
similar to those in the main analysis. Owing to limita-
tions in power, it was not possible to conclude whether 
there were differences between the current and past 
use categories.
Additionally, the ability of our study to draw conclu-
sions on specific infections was limited because of 
issues with power. Several point estimates were high 
but not statistically significantly increased. However, 
the absence of significant associations does not provide 
evidence that risk is not increased. Lastly, our study 
was not powered to study either opportunistic infec-
tions as a separate outcome, cause specific death, or the 
different TNF-α inhibitors separately.
Comparison to other studies
In previous population based studies, the answer as to 
whether TNF-α inhibitor treatment is associated with an 
increased risk of serious infections in people with inflam-
matory bowel disease has been conflicting.13 14 26 27 
A study from the American TREAT (Crohn’s Therapy, 
Resource, Evaluation, and Assessment Tool) registry 
assessed the risk of serious infections among 2853 
patients treated with infliximab for Crohn’s disease, 
with a mean follow-up time of 5.2 years14  and found that 
treatment was an independent risk factor for serious 
infections (hazard ratio 1.43, 95% confidence interval 
1.11 to 1.84). Another register based cohort study based 
on the SABER (Safety Assessment of Biologic Therapy) 
initiative13 examined rates of serious infection in 2323 
people treated with TNF-α inhibitors for inflammatory 
bowel disease compared with propensity score matched 
patients receiving non-biological comparator drugs 
(azathioprine/mercaptopurine). This study found no 
significantly increased risk of infections associated 
with TNF-α inhibitor treatment (hazard ratio 1.10, 95% 
confidence interval 0.83 to 1.46); with a similar risk 
throughout the year of follow-up and hence no sugges-
tion of an initially increased risk. In general, the varia-
tions in risk estimates observed in observational studies 
may be due to differences in the background rates of 
infections in the studied populations. For example, a 
high incidence rate of serious infections was observed 
table 3 | Hazard ratios for site specific infections comparing matched users and non-users of tumour necrosis factor-α 
(tnF-α) inhibitors within a 365 days risk period
infection sites
users of tnF-α inhibitors non-users of tnF-α inhibitors Hazard ratio  
(95% Ci)no of patients no of events no of patients no of events
Gastrointestinal 1543 28 1543 24 1.01 (0.55 to 1.86)
Respiratory tract 1543 30 1543 28 0.75 (0.42 to 1.34)
Skin and soft tissue 1543 26 1543 13 2.51 (1.23 to 5.12)
Urological or 
gynaecological 
1543 9 1543 4 2.31 (0.64 to 8.29)
Sepsis 1543 6 1543 4 2.45 (0.65 to 9.19)
Other 1543 8 1543 5 1.24 (0.36 to 4.30)
table 4 | Hazard ratios for any serious infection in matched tumour necrosis factor-α (tnF-α) inhibitor users and 
azathioprine users
risk period
users of tnF-α inhibitors users of azathioprine Hazard ratio  
(95% Ci)no of patients no of events no of patients no of events
90 days 268 12 268 7 2.17 (0.85 to 5.52)
365 days 268 18 268 11 2.05 (0.97 to 4.36)
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in the comparison group in the SABER cohort, probably 
as a result of the predominance of low income and vul-
nerable patients in the cohort and the findings may 
therefore primarily be applicable to this population. In 
our study we were able to obtain data on the entire Dan-
ish population with inflammatory bowel disease where 
everyone has equal access to medical care and treat-
ment (including with TNF-α inhibitors); hence we 
believe our observations apply to the broader popula-
tion with inflammatory bowel disease.
We observed an increased risk after 90 days of 
 follow-up that declined within 365 days following the 
start of treatment with TNF-α inhibitors as well as 
decreasing hazard ratios with increasing number of 
accumulated TNF-α inhibitor doses. This risk pattern 
resembles that suggested by several studies evaluating 
the association between TNF-α inhibitors and risk of 
serious infections in people with rheumatoid arthri-
tis.7-10 The decline in risk over time may be because 
TNF-α inhibitor treatment actually causes early, but not 
late, infections in susceptible people. However, it may 
also partly be explained by detection bias, as clinicians 
may have a lower threshold for identifying infections 
early in the course of TNF-α inhibitor treatment. Lastly, 
it may be due to a depletion of people susceptible to 
infection (that is, high risk people have infections early 
and discontinue treatment, hence leaving a cohort that 
is at lower risk of infection); these theories need further 
investigation.
The significantly increased risk of skin and soft tissue 
infections observed in our study is not unexpected, as 
an association between TNF-α inhibitor treatment and 
skin and soft tissue infections has been shown previ-
ously.28 29 However, although power was limited, our 
analyses of site specific infections indicated a possible 
increased risk of not only skin and soft tissue infections 
but also several other infection types. Considering the 
central role of TNF-α inhibitors in host defence, suscep-
tibility to infections in people treated with drugs inhib-
iting this cytokine is biologically plausible. However, 
whether the physiological role of TNF-α inhibitors in 
host defence varies between tissues leading to 
increased risk of some specific infections but not others 
is not clear and calls for further research.
Conclusion
In this population based nationwide cohort study of 
people with inflammatory bowel disease we found that 
use of TNF-α inhibitors was associated with a modestly 
increased risk of serious infections within the first 90 
days after the start of treatment, which declined with 
prolonged follow-up. The results suggest that clinical 
vigilance of potential infectious complications is indi-
cated in people treated with TNF-α inhibitors for inflam-
matory bowel disease, especially early in the course of 
treatment.
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